



Inflammatory oedema induced by phospholipases A₂ isolated from *Crotalus durissus* sp. in the rat dorsal skin: a role for mast cells and sensory C-fibers

Paula R.S. Câmara^a, Laura C.M. Esquisatto^b, Enilton A. Camargo^b, Maria Teresa C.P. Ribela^c, Marcos H. Toyama^a, Sergio Marangoni^a, Gilberto De Nucci^b, Edson Antunes^{b,*}

^aDepartment of Biochemistry, Institute of Biology, UNICAMP, Campinas, SP, Brazil

^bDepartment of Pharmacology, Faculty of Medical Sciences, UNICAMP, P.O. Box 6111, Campinas, SP 13081-970, Brazil

^cDepartment of Application of Nuclear Techniques in Biological Sciences, IPEN/CNEN, São Paulo, Brazil

Received 27 September 2002; accepted 11 February 2003

Abstract

The ability of the phospholipases A₂ (PLA₂s) from *Crotalus durissus cascavella*, *Crotalus durissus collilineatus* and *Crotalus durissus terrificus* venoms and crotapotin to increase the vascular permeability in the rat skin as well as the contribution of both mast cells and sensory C-fibers have been investigated in this study. Vascular permeability was measured as the plasma extravascular accumulation at skin sites of intravenously injected ¹²⁵I-human serum albumin. Intradermal injection of crotalic PLA₂s (0.05–0.5 μg/site) in the rat skin resulted in dose-dependent increase in plasma extravascular whereas crotapotin (1 μg/site) failed to affect this response. Co-injection of crotapotin (1 μg/site) did not modify the increased vascular permeability induced by the PLA₂s (0.05–0.5 μg/site). Previous treatment (30 min) of the animals with cyproheptadine (2 mg/kg, i.p.) markedly reduced PLA₂ (0.5 μg/site)-induced oedema. In rats treated neonatally with capsaicin to deplete neuropeptides, the plasma extravasation induced by all PLA₂s (0.5 μg/site) was also significantly reduced. Similarly, the tachykinin NK₁ receptor antagonist SR140333 (1 nmol/site) significantly reduced the PLA₂-induced oedema. In addition, the combination of SR140333 with cyproheptadine further reduced the increased plasma extravasation by PLA₂ from *C. d. cascavella* venom, but not by PLA₂ from *C. d. terrificus* and *C. d. collilineatus* venoms. Our results suggest that increase in skin vascular permeability by crotalic PLA₂s is mediated by activation of sensory C-fibers culminating in the release of substance P, as well as by activation of mast cells which in turn release amines such as histamine and serotonin.

© 2003 Elsevier Science Ltd. All rights reserved.

Keywords: Neurogenic inflammation; Mast cells; Phospholipase A₂; Venoms; Sensory fibers

1. Introduction

Secretory phospholipases A₂ (PLA₂s) are a broad group of enzymes intensely studied due to their potential involvement in the production of inflammatory mediators, such as prostaglandins, prostacyclin, thromboxane A₂,

leukotrienes and platelet-activating factor. In recent years, several additional forms of PLA₂s have been discovered (Six and Dennis, 2000). At the present time, they are divided into 11 groups based on their structure similarity and localization. Venom PLA₂s are comprised into three main groups, namely type I (purified from Elapidae and Hydrophidae venoms), type II (purified from Crotalidae venoms) and type III (purified from bee and wasp venoms). Type II PLA₂s can be subdivided into Asp-49 PLA₂s and Lys-49-like proteins, the former of which contains an

* Corresponding author. Tel.: +55-19-3788-9556; fax: +55-19-3289-2968.

E-mail address: edson.antunes@uol.com.br (E. Antunes).

aspartic acid residue at the calcium binding site and high enzymatic activity whereas the latter contains lysine at the position 49 and very little or no enzymatic activity (Ownby et al., 1999). Venom PLA₂s cause local inflammatory effects characterized mainly by increase in vascular permeability (Cirino et al., 1989; Wang and Teng, 1990; Moreno et al., 1992; Landucci et al., 1998, 2000a,b; Chaves et al., 1998) and leukocyte infiltration into tissues (Vadas et al., 1989; Bomalaski et al., 1991; Lomonte et al., 1993; Castro et al., 2000) which take place by mechanisms dependent and independent of the catalytic activity.

Crotoxin is the main neurotoxic component isolated from *Crotalus durissus* sp. venom, representing approximately 50% of the venom protein. Crotoxin consists of a reversible protein complex composed of two non-identical sub-units, a basic phospholipase A₂ (PLA₂) and an acidic non-enzymatic component named crotapotin (Rubsamen et al., 1971; Hendon and Fraenkel-Conrat, 1976). The crotapotin component is reported to be pharmacologically inactive and is thought to act as a chaperon protein for PLA₂ increasing the biological activities of this enzyme (Haber-mann and Breithaupt, 1978). There are several isoforms of crotoxin that are believed to be a consequence of random association of the PLA₂ with crotapotin, possibly resulting from a post-translation modification of a unique precursor of crotoxin or expression of different mRNA (Faure et al., 1991, 1994). The objective of this study was first to examine the ability of the novel described PLA₂s from *Crotalus durissus cascavella* and *Crotalus durissus collilineatus* venoms (Beghini et al., 2000; Ponce-Soto et al., 2002) to increase the vascular permeability in the rat skin in absence and presence of crotapotin in comparison with that of *C. d. terrificus* venom (Landucci et al., 1994). Second, to explore the contribution of mast cells and sensory C-fibers to the increased permeability induced by these PLA₂s.

2. Materials and methods

2.1. Measurement of rat dorsal skin oedema

Experiments were performed in male Wistar rats (200–300 g). All experiments were carried out in accordance with the guidelines for animal care of the State University of Campinas (UNICAMP). The animals were anaesthetised with sodium pentobarbitone (50 mg kg⁻¹, given i.p.) and maintenance doses were administered when required. Local plasma protein extravasation was measured in the shaved dorsal rat skin, in response to intradermally injected PLA₂s or other agents (100 µl/site in Tyrode solution), according to Brain and Williams (1985). Agents were injected in a random order, according to a balanced site pattern. Plasma protein extravasation was measured by the accumulation of intravenously injected (i.v.) ¹²⁵I-human serum albumin (¹²⁵I-HSA; 2.5 µCi rat⁻¹) with Evan's blue dye

(25 mg kg⁻¹) to act as a visual marker. Antagonists and other test agents were injected as required by specific protocols. At the end of the accumulation period (30 min), a cardiac blood sample (5 ml) was taken and the rats killed by anaesthetic overdose. The blood samples were centrifuged at 8000g for 10 min to obtain a plasma sample. The injected sites were punched out and counted for radioactivity, with the plasma samples in a γ-counter. Plasma extravasation was expressed as the volume (µl) of plasma accumulated at each skin site compared to total counts in 1 ml of plasma.

2.2. Neonatal treatment of rats with capsaicin

Neonates Wistar rats (7–8 g) were pretreated on the second day of life by a single subcutaneous (s.c.) injection of capsaicin (50 mg/kg) under ether anaesthesia. Control animals were pretreated with the corresponding volume (0.1 ml) of capsaicin-vehicle (1:1:8; Ethanol:Tween 80:NaCl solution v/v), as previously described (Jancsó et al., 1977). Both male and female rats were used 60–70 days later.

2.3. Drugs

The PLA₂s and crotapotins used in our study were isolated in house according to previous studies (Landucci et al., 1994; Beghini et al., 2000; Ponce-Soto et al., 2002). They show similar molecular mass, hydrophilicity and hydrophobicity for all the venoms used. Capsaicin, cyproheptadine, compound 48/80 and substance P were purchased from Sigma Chemical Co. (St Louis, MO, USA) ¹²⁵I-Human serum albumin was radio-labelled in IPEN/CENEN-USP (São Paulo, Brazil). Sodium pentobarbitone was purchased from Rhone Merieux (Dublin, Ireland). SR140333 ((S)-1-(2-(3-(3,4-dichlorophenyl)-1-(3-iso-propoxyphenylacetyl) piperidine-3-yl)ethyl)-4-phenyl-1-azoniabicyclo(2.2.2) octone, chloride) and SR48968 ((S)-N-methyl-N-(4-(4-acetylamino-4-phenylpiperidino)-2-(3,4-dichlorophenyl)butyl)benzamide) were provided by Sanofi Recherche (Montpellier, France). Crotalic PLA₂s and test-agents were stored at –20 °C and diluted with modified Tyrode solution prior to use. The Tyrode composition was (in mM): NaCl, 137; KCl, 2.7; MgCl₂, 0.5; NaH₂PO₄, 0.4; NaHCO₃, 11.9 and glucose, 5.6.

2.4. Statistical analysis

Results are presented as mean values ± SEM for *n* experiments. The values were analysed by Student's unpaired *t* test or ANOVA followed by Bonferroni's modified *t* test. *P* < 0.05 was taken as significant.




Fig. 1. Rat skin plasma protein extravasation induced by PLA₂s from *C. d. terrificus*, *C. d. collilineatus* and *C. d. cascavella* venoms at the doses of 0.05 (open columns), 0.1 (hatched columns), 0.25 (cross-hatched columns) and 0.5 µg/site (dotted columns). Results are expressed as µl plasma extravasated per site and each point represents the mean ± SEM of 7–12 animals. **P* < 0.05, ***P* < 0.01, ****P* < 0.001 compared to Tyrode (dotted line).

3. Results

3.1. Effect of intradermal injection of crotalic PLA₂s and crotopotin

Intradermal injection of PLA₂s from venoms of *C. d. durissus*, *C. d. cascavella* or *C. d. collilineatus* (0.05–0.5 µg/site; *n* = 5) in the rat dorsal skin induced a dose-dependent plasma extravasation in the rat dorsal skin, which was significantly different from that achieved by i.d. administration of Tyrode (Fig. 1).

Intradermal injection of crotopotin (isolated from *C. d. terrificus* venom) had no significant effect on the plasma protein extravasation (21.5 ± 2.5, 33.7 ± 5.1 and 35.6 ± 8.0 µl for 0.3, 1.0 and 3.0 µg/site, respectively), compared to Tyrode (21.7 ± 2.4, *n* = 5). Crotopotin isolated from *C. d. cascavella* or *C. d. collilineatus* venoms also failed to significantly affect the plasma extravasation (23.5 ± 5.5 and 23.6 ± 6.2 µl for 1.0 µg/site, respectively; *n* = 5) compared to Tyrode.

In addition, crotopotin (1 µg/site; isolated from *C. d. terrificus* venom) did not significantly modify the plasma extravasation induced by *C. d. terrificus* venom PLA₂

(0.05–0.5 µg/site; Table 1). Similarly, the crotopotins (1 µg/site) isolated from *C. d. cascavella* or *C. d. collilineatus* venoms had no significant effect on the plasma extravasation induced by their correspondent PLA₂ (Table 1). The combination of the crotopotin (1 µg/site) isolated from *C. d. terrificus* venom with the PLA₂ (0.5 µg/site) isolated from *C. d. cascavella* or *C. d. collilineatus* venoms (or other mixture of crotopotin with non-correspondent PLA₂s) also failed to affect the plasma extravasation (not shown; *n* = 5).

3.2. Role of mast cells

In rats pretreated (30 min before) with cyproheptadine (2 mg/kg, i.p.), a histamine H₁ and 5-HT receptor antagonist, the plasma extravasation evoked by the mast cell degranulator compound 48/80 (0.5 µg/site) was nearly abolished (76.2 ± 11.8 and 14.4 ± 4.9 µl, for control and treated-sites, respectively; *n* = 5), whereas that of substance P (1 nmol/site) was not significantly changed (56.3 ± 4.2 and 48.4 ± 7.0 µl, for control and treated-sites, respectively; *n* = 4). In these cyproheptadine-treated rats, the plasma extravasation in response to PLA₂s

Table 1

Lack of effect of crotopotin (CA; 1.0 µg/site) on the skin oedema induced by phospholipases A₂ (PLA₂) from *C. d. terrificus*, *C. d. cascavella* and *C. d. collilineatus* venoms (0.05–0.5 µg/site)

µg/site	<i>C. d. terrificus</i> PLA ₂		<i>C. d. cascavella</i> PLA ₂		<i>C. d. collilineatus</i> PLA ₂	
	–CA	+CA	–CA	+CA	–CA	+CA
0.05	54.2 ± 7.0	61.2 ± 8.1	54.6 ± 3.6	61.6 ± 5.6	44.7 ± 5.3	63.1 ± 5.2
0.1	65.0 ± 5.4	66.3 ± 5.4	66.5 ± 2.9	68.4 ± 7.9	48.2 ± 6.0	57.4 ± 4.5
0.25	82.0 ± 5.0	84.0 ± 9.0	83.8 ± 8.9	72.0 ± 9.7	76.4 ± 2.4	83.7 ± 8.8
0.5	73.3 ± 4.5	64.8 ± 7.4	77.7 ± 1.6	92.2 ± 3.4	87.4 ± 7.6	61.8 ± 5.3

Each PLA₂ was co-injected with its correspondent crotopotin. Results are expressed as mean values ± SEM of five rats.




Fig. 2. Inhibitory effect of cyproheptadine (2 mg/kg, i.p.; solid columns), SR48968 (1 nmol/site; squared columns), SR140333 (1 nmol/site; hatched columns) or combination of cyproheptadine (2 mg/kg) plus SR140333 (1 nmol/site; cross-hatched columns) on plasma protein extravasation induced by PLA₂ (0.5 µg/site) from *C. d. terrificus*, *C. d. collilineatus* and *C. d. cascavella* venoms. Results are expressed as µl plasma extravasated per site and each point represents the mean ± SEM of 4–9 animals. * $P < 0.01$, compared to untreated rats. ** $P < 0.05$ compared to rats treated with either cyproheptadine or SR140333.

from *C. d. terrificus*, *C. d. cascavella* and *C. d. collilineatus* venoms (0.5 µg/site each; $n = 9$) was reduced by 53.3, 74.8 and 52.6%, respectively ($P < 0.01$; Fig. 2).

3.3. Effect of tachykinin NK₁ receptor antagonist and of capsaicin pretreatment

The plasma extravasation evoked by substance P (1 nmol/site; 74.5 ± 9.9 µl) was markedly reduced ($P < 0.01$) by the co-injection with the tachykinin NK₁ receptor antagonist SR140333, at a dose of 1 nmol/site (24.8 ± 5.5 µl; $n = 5$). At this dose of SR140333, the plasma extravasation induced by PLA₂s from *C. d. terrificus*, *C. d. cascavella* and *C. d. collilineatus* venoms (0.5 µg/site each) was significantly inhibited (Fig. 2; $n = 5$). The tachykinin NK₂ receptor antagonist SR48968 (1 nmol/site, $n = 5$) affected neither the plasma extravasation induced by substance P (not shown) nor by PLA₂ from *C. d. terrificus*, *C. d. cascavella* and *C. d. collilineatus* venoms (Fig. 2; $n = 4$). In addition, the combination of SR140333 (1 nmol/site) with cyproheptadine (2 mg/kg, i.p.) did not further reduce the increased plasma extravasation by PLA₂ from *C. d. terrificus* and *C. d. collilineatus* venoms, except for *C. d. cascavella* venom PLA₂, where a greater inhibition was observed (Fig. 2). Additionally, the increased plasma extravasation induced by compound 48/80 (0.5 µg/site) was significantly ($P < 0.05$) reduced by SR140333 (1 nmol/site; 61.1 ± 4.2 and 32.5 ± 2.9 µl for control and treated-sites, respectively; $n = 4-6$).

The role of capsaicin sensitive primary afferent neurones in response to crotalic PLA₂s in dorsal skin was tested in rats treated at neonatal stage with capsaicin to deplete neuropeptides. Fig. 3 shows that a significant inhibition of

plasma extravasation in capsaicin-pretreated rats was observed in response to all crotalic PLA₂s (0.5 µg/site) as compared to the response seen in control rats. The substance P (1 nmol/site)-induced plasma extravasation was unmodified in capsaicin-pretreated rats as compared to the values seen in control rats ($n = 5$).

4. Discussion

Our results demonstrate that secretory PLA₂s isolated from venoms of *C. d. terrificus*, *C. d. cascavella* and *C. d. collilineatus* are able to increase the microvascular permeability in the rat dorsal skin by mechanisms involving activation of local mast cells and sensory C-fibers. Previous studies have demonstrated that other snake venom PLA₂s are able to activate mast cells in vivo (Cirino et al., 1989; Wang and Teng, 1990; Moreno et al., 1992) and in vitro (Lau and Roche, 1997; Landucci et al., 1998, 2000a,b; Castro et al., 2000) increasing plasma extravasation in the rat due to release of histamine and serotonin; however, no studies until now have reported the involvement of capsaicin-sensitive primary afferent fibers (C-fibers; Holzer, 1998) as target for snake venom PLA₂s.

The non-adrenergic non-cholinergic innervation is primarily constituted by capsaicin-sensitive sensory C-fibers that are found beneath and within the epithelium, around blood vessels and submucosal glands. It is well established that acute electrical or chemical (capsaicin) stimulation of sensory nerve fibres leads to neuropeptide release (e.g. tachykinins such as substance P and also calcitonin gene related peptide) that can mediate local neurogenic inflammatory effects in the innervated tissues (Escott and Brain,




Fig. 3. Effect of neonatal capsaicin-pretreatment on plasma protein extravasation induced by PLA₂s (0.5 µg/site) from *C. d. terrificus*, *C. d. collilineatus* and *C. d. cascavella* venoms. Response to venom PLA₂s in control and capsaicin-pretreated rats is showed by the open and cross-hatched columns, respectively. The results are expressed as the mean ± SEM of five rats. * $P < 0.05$, *** $P < 0.01$ compared to vehicle.

1993). Capsaicin (8 methyl-*N*-vanillyl-6-nonenamide) is a pungent ingredient contained in a wide variety of red peppers of the genus *Capsicum* and excites a subset of primary sensory neurons with somata in dorsal root ganglion or trigeminal ganglion via the VR1 receptors, a subgroup of the transient receptor potential family of ion channels (Szallasi and Blumberg, 1999; Gunthorpe et al., 2002). Capsaicin stimulates the peripheral terminals of C-fibers causing the release of the neuropeptides, thus initiating the cascade of neurogenic inflammation. When given to newborn rats, capsaicin degenerates the neurons located in dorsal root ganglion (Jancsó et al., 1977) and, therefore, has largely been used to identify capsaicin-sensitive neuronal pathways and to explore their contributions to evaluate sensory neuron mechanisms (Holzer, 1998). Substance P and NK₁ receptor agonists act primarily via the tachykinin receptors to mediate vasoactive responses in post-capillaries venules. They are potent mediators of increased permeability and, as a consequence, oedema formation (Brain, 1996). Our findings that plasma extravasation induced by all crotalic PLA₂s was significantly reduced in capsaicin-pretreated rats indicate that part of their exudative response requires integrity of the sensory fibers supplying the cutaneous microcirculation, and suggest that neurogenic mediators (mainly substance P) may be released in response to PLA₂s. It is thus likely that such proteins act directly (or indirectly) to activate sensory neurons to release the tachykinin NK₁ receptor agonist substance P. This is further supported by our results showing that SR140333, a selective NK₁ receptor antagonist (Emonds-Alt et al., 1993), significantly inhibited the PLA₂s-induced oedema.

It has been demonstrated that substance P-induced plasma extravasation results from a direct action of this peptide on the endothelium of postcapillary venules (tachykinin NK₁ receptors) and on the release of histamine and serotonin from mast cells. Mast cell activation is an

intermediate step in the sensory nerve-mediated neurogenic responses (Foreman et al., 1983). It has been attributed mainly to the close anatomical contact between sensory nerves and mast cells (Botchkarev et al., 1997). Substance P can induce in vivo and in vitro mast cell degranulation, resulting in the local release of the vasoactive amines (Devillier et al., 1989; Holzer, 1998). Activation of mast cells by substance is triggered by receptor-independent mechanisms involving direct interaction with G proteins, and reflects electrostatic interaction between positive charges of this peptide with the negative charges of the mast cell surface (Ferry et al., 2002). A previous study showed that lower doses of substance P causes an oedema dependent on the direct activation of NK₁ receptors, whereas at higher doses this peptide evokes oedema through the release of secondary mediators, possibly from mast cells (Walsh et al., 1995). This suggests that mast cell degranulation by these peptides may account for the inflammatory actions of PLA₂s, a proposal corroborated by our findings that treatment of the animals with cyproheptadine markedly inhibited these inflammatory responses. It is known that mast cell-derived agents (i.e. histamine, 5-HT and tryptase) are potentially able to stimulate sensory neurons to release substance P (Saria et al., 1984) further amplifying the inflammatory response (Steinhoff et al., 2000). However, we cannot ascertain from our study whether in vivo activation of sensory C-fibers by the PLA₂s reflects a direct action of these proteins in the nerve endings or via mast cells to stimulate neuropeptide release, or both of these mechanisms. The reduction by SR140333 of plasma extravasation induced by compound 48/80 (a potent mast cell activator) in the rat skin may suggest the mast cell constituents play an important role in PLA₂-induced oedema. At this point, it is unclear why concomitant blockade of tachykinin NK₁ and histamine/serotonin receptors by the use of SR140333 and

cyproheptadine did not further reduce the increased plasma extravasation by PLA₂ from *C. d. terrificus* and *C. d. collilineatus* venoms, but did so only with the PLA₂ from *C. d. cascavella*.

Crotapotin is a protein naturally found complexed with a basic PLA₂, and the resulting complex (crotoxin) is responsible for the potent neurotoxic activity present in the rattlesnake venoms. Crotapotin may act as chaperon protein for the PLA₂, increasing the lethal neurotoxic effects of PLA₂s (Bon, 1982). Previous studies demonstrated that crotapotin increases the lethal potency of agkistrodotoxin (a β-neurotoxin PLA₂) and modifies the pharmacological effects of this toxin on *Torpedo* synaptosomes (Choumet et al., 1993). Our results showed that crotapotin did not significantly modify the plasma extravasation of crotalic PLA₂s in the rat skin. This is surprising since our previous studies showed that crotapotin inhibits the rat paw oedema induced by PLA₂s from both *Naja Naja* and *Apis mellifera* venoms (Landucci et al., 2000) as well as the carrageenin-induced rat paw oedema (Landucci et al., 1995). Nevertheless, in vitro interaction of purified PLA₂ and crotapotin restoring the native crotoxin complex with the same potency and biological actions has been proven to be difficult to demonstrate. Provided crotapotin inhibits the in vitro enzymatic activity of different venom PLA₂s (Landucci et al., 2000), including that from *C. d. terrificus* (personal communication), we may speculate that activation of sensory C-fibers and/or mast cells by the PLA₂s takes place by mechanisms independent of their catalytic activity. The existence of M (muscle)- and N (neuronal)-type receptors for PLA₂ have been identified and cloned in both experimental animal and humans, thus suggesting the existence of novel physiopathological functions for mammalian secretory PLA₂ unrelated to their enzymatic activity (Lambeau and Lazdunski, 1999). Whether venom PLA₂s increase vascular permeability by binding to one (or both) of these receptors in sensory terminals and/or mast cells remains to be elucidated.

References

- Beghini, D.G., Toyama, M.H., Hyslop, S., Sodek, L., Novello, J.C., Marangoni, S., 2000. Enzymatic characterization of a novel phospholipase A₂ from *Crotalus durissus cascavella* rattlesnake (Maracaboia) venom. *J. Protein Chem.* 19, 603–607.
- Bomalaski, J.S., Lawton, P., Browning, J.L., 1991. Human extracellular recombinant phospholipase A₂ induces an inflammatory response in rabbit joints. *J. Immunol.* 146, 3904–3910.
- Bon, C., 1982. Synergism of the two subunits of crotoxin. *Toxicon* 2, 105–109.
- Botchkarev, V.A., Eichmuller, S., Peters, E.M., Pietsch, P., Johansson, O., Maurer, M., Paus, R.A., 1997. Simple immunofluorescence technique for simultaneous visualization of mast cells and nerve fibers reveals selectivity and hair cycle-dependent changes in mast cell–nerve fiber contacts in murine skin. *Arch. Dermatol. Res.* 289, 292–302.
- Brain, S.D., 1996. Sensory neuropeptides in the skin. In: Geppetti, P., Holzer, P. (Eds.), *Neurogenic Inflammation*, CRC Press, Boca Raton, FL, pp. 229–244.
- Brain, S.D., Williams, T.J., 1985. Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability. *Br. J. Pharmacol.* 86, 855–860.
- Castro, R.C., Landucci, E.C.T., Toyama, M.H., Giglio, J.R., Marangoni, S., De Nucci, G., Antunes, E., 2000. Leucocyte recruitment induced by type II phospholipases A₂ into the rat pleural cavity. *Toxicon* 38, 1773–1785.
- Chaves, F., Leon, G., Alvarado, V.H., Gutierrez, J.M., 1998. Pharmacological modulation of oedema induced by Lys-49 e asp-49 myotoxic phospholipase A₂ isolated from venom of the snake *Bothrops asper* (terciopelo). *Toxicon* 36, 1861–1869.
- Choumet, V., Saliou, B., Fideler, L., Chen, Y.C., Gubensek, F., Bon, C., Delot, E., 1993. Snake-venom phospholipase A₂ neurotoxins. Potentiation of a single-chain crotoxin by the chaperon subunit of a two-component neurotoxin. *Eur. J. Biochem.* 211, 57–62.
- Cirino, G., Peers, S.H., Wallace, J.L., Flower, R.J., 1989. A study of phospholipase A₂-induced oedema in rat paw. *Eur. J. Pharmacol.* 166, 505–510.
- Devillier, P., Drapeau, G., Renoux, M., Regoli, D., 1989. Role of the N-terminal arginine in the histamine-releasing activity of substance P, bradykinin and related peptides. *Eur. J. Pharmacol.* 168, 53–60.
- Emonds-Alt, X., Dautrempuich, J.D., Heulme, M., Neliat, G., Santucci, V., Steinberg, R., Vilain, P., Bichon, D., Ducoux, J.P., Proietto, V., Van Broeck, D., Soubrière, P., Le Fur, G., Brelière, J.C., 1993. In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK₁ receptor antagonist. *Eur. J. Pharmacol.* 250, 403–413.
- Escott, K.J., Brain, S.D., 1993. Effect of a calcitonin gene-related peptide antagonist (CGRP_{8–37}) on skin vasodilatation and oedema induced by stimulation of the rat saphenous nerve. *Br. J. Pharmacol.* 110, 772–776.
- Faure, G., Guillaume, J.L., Camoin, L., Saliou, B., Bon, C., 1991. Multiplicity of acidic subunit isoforms of crotoxin, the phospholipase A₂ neurotoxin from *Crotalus durissus terrificus* venom, results from posttranslational modifications. *Biochemistry* 30, 8074–8083.
- Faure, G., Choumet, V., Bouchier, C., Camoin, L., Guillaume, J.L., Monegier, B., Vuilhorgne, M., Bon, C., 1994. The origin of the diversity of crotoxin isoforms in the venom of *Crotalus durissus terrificus*. *Eur. J. Biochem.* 223, 161–164.
- Ferry, X., Brehin, S., Kamel, R., Landry, Y., 2002. G protein-dependent activation of mast cell by peptides and basic secretagogues. *Peptides* 23, 1507–1515.
- Foreman, J.C., Jordan, C.C., Oehme, P., Renner, P., 1983. Structure-activity relationships for some substance P-related peptides that cause wheal and flare reactions in human skin. *J. Physiol.* 335, 449–465.
- Gunthorpe, M.J., Benham, C.D., Randall, A., Davis, J.B., 2002. The diversity in the vanilloid (TRPV) receptor family of ion channels. *Trends Pharmacol. Sci.* 23, 183–191.
- Habermann, E., Breithaupt, H., 1978. The crotoxin complex: an example of biochemical and pharmacological protein complementation. *Toxicon* 16, 19–30.

- Hendon, R.A., Fraenkel-Conrat, H., 1976. The role of complex formation in the neurotoxicity of crotoxin components A and B. *Toxicon* 14, 283–289.
- Holzer, P., 1998. Neurogenic vasodilatation and plasma leakage in the skin. *Gen. Pharmacol.* 30, 5–11.
- Jancsó, G., Kiraly, E., Jankos-Gabor, A., 1977. Pharmacologically induced selective degeneration of chemosensitive primary sensory neurones. *Nature* 270, 741–742.
- Lambeau, G., Lazdunski, M., 1999. Receptors for a growing family of secreted phospholipases A₂. *Trends Pharmacol. Sci.* 20, 162–170.
- Landucci, E.C.T., Condino-Neto, A., Perez, A.C., Hyslop, S., Corrado, A.P., Novello, J.C., Marangoni, S., Oliveira, B., Antunes, E., De Nucci, G., 1994. Crotoxin induces aggregation of human washed platelets. *Toxicon* 32, 217–226.
- Landucci, E.C.T., Antunes, E., Donato, J.L., Faro, R., Hyslop, S., Marangoni, S., Oliveira, B., Cirino, G., De Nucci, G., 1995. Crotopotin, a polypeptide complexed with phospholipase A₂, inhibits carrageenin-induced rat paw oedema. *Br. J. Pharmacol.* 114, 578–583.
- Landucci, E.C.T., Pereira, M.F., Cintra, A.C.O., Giglio, J.R., Marangoni, S., Oliveira, B., Cirino, G., Antunes, E., De Nucci, G., 1998. Mast cell degranulation induced by two phospholipase A₂ homologues: dissociation between enzymatic and biological activities. *Eur. J. Pharmacol.* 343, 257–263.
- Landucci, E.C.T., Castro, R.C., Toyama, M., Giglio, J.R., Marangoni, S., De Nucci, G., Antunes, E., 2000a. Inflammatory oedema induced by the Lys-49 phospholipase A₂ homologue piratoxin-I in the rat and rabbit: effect of polyanions and *p*-bromophenacyl bromide. *Biochem. Pharmacol.* 59, 1289–1294.
- Landucci, E.C.T., Toyama, M., Marangoni, S., Oliveira, B., Cirino, G., Antunes, E., De Nucci, G., 2000b. Effect of crotopotin and heparin on the rat paw oedema induced by different secretory phospholipases A₂. *Toxicon* 38, 199–208.
- Lau, H.Y., Roche, C.M., 1997. Effects of secretory phospholipase A₂ enzymes on mast cells of rat, guinea pig and human. *Inflamm. Res.* 46, S19–S20.
- Lomonte, B., Tarkowski, A., Hanson, L.A., 1993. Host response to *Bothrops asper* snake venom. Analysis of edema formation, inflammatory cells, and cytokine release in a mouse model. *Inflammation* 17, 93–105.
- Moreno, J.J., Ferre, X., Ortega, E., Carganico, G., 1992. Phospholipase A₂-induced oedema in rat skin and histamine release mast cells. Evidence for involvement of lysophospholipids in the mechanism of action. *Agents Act.* 36, 258–263.
- Ownby, C.L., Selistre de Araujo, H.S., White, S.P., Fletcher, J.E., 1999. Lysine 49 phospholipase A₂ proteins. *Toxicon*, 411–445.
- Ponce-Soto, L.A., Toyama, M.H., Hyslop, S., Novello, J.C., Marangoni, S., 2002. Isolation and preliminary enzymatic characterization of a novel phospholipase A₂ from *Crotalus durissus collilineatus* venom. *J. Protein Chem.* 21, 131–136.
- Rubsamen, K., Breithaupt, H., Habermann, E., 1971. Biochemistry and pharmacology of the crotoxin complex. I. Subfractionation and recombination of the crotoxin complex. *Naunyn Schmiedeberg Arch. Pharmacol.* 270, 274–288.
- Saria, A., Hua, X., Skofitsch, G., Lundberg, J.M., 1984. Inhibition of compound 48/80-induced vascular protein leakage by pretreatment with capsaicin and a substance P antagonist. *Naunyn Schmiedeberg Arch. Pharmacol.* 328, 9–15.
- Six, D.A., Dennis, E.A., 2000. The expanding superfamily of phospholipase A₂ enzymes: classification and characterization. *Biochim. Biophys. Acta* 1488, 1–19.
- Steinhoff, M., Vergnolle, N., Young, S.H., Tognetto, M., Amadesi, S., Ennes, H.S., Trevisani, M., Hollenberg, M.D., Wallace, J.L., Caughey, G.H., Mitchell, S.E., Williams, L.M., Geppetti, P., Mayer, E.A., Bunnett, N.W., 2000. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. *Nat. Med.* 6, 151–158.
- Szallasi, A., Blumberg, P.M., 1999. Vanilloid (capsaicin) receptors and mechanisms. *Pharmacol. Rev.* 51, 159–211.
- Vadas, P., Pruzanski, W., Kim, J., Fornasier, V., 1989. The proinflammatory effect of intra-articular injection of soluble human and venom phospholipase A₂. *Am. J. Pathol.* 134, 807–811.
- Walsh, D.T., Weg, V.B., Williams, T.J., Nourshargh, S., 1995. Substance P-induced inflammatory responses in guinea-pig skin: the effect of specific NK1 receptor antagonists and the role of endogenous mediators. *Br. J. Pharmacol.* 114, 1343–1350.
- Wang, J.P., Teng, C.M., 1990. Comparison of the enzymatic and edema-producing activities of two venom phospholipase A₂ enzymes. *Eur. J. Pharmacol.* 190, 347–354.